PANLAR: Patients with GPA, MPA should use rituximab over cyclophosphamide

Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.
“Over the past 30 years, randomized controlled trials have helped to delineate the treatment of ANCA-associated vasculitis, particularly for patients with GPA and MPA,” Sebastián Juan Magri, MD, of the Hospital Italiano de La Plata, in Buenos Aires, and colleagues wrote in The Lancet Rheumatology. “Once highly fatal, ANCA-associated vasculitis

Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.
“Over the past 30 years, randomized controlled trials have helped to delineate the treatment of ANCA-associated vasculitis, particularly for patients with GPA and MPA,” Sebastián Juan Magri, MD, of the Hospital Italiano de La Plata, in Buenos Aires, and colleagues wrote in The Lancet Rheumatology. “Once highly fatal, ANCA-associated vasculitis